Inhibitory effects of tolerogenic probiotics on migratory potential of lupus patient-derived DCs

Document Type : Original Article


1 Immunology Research Center, Bu‐Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran

2 Immunology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Nanobiotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

4 Department of Medical Biotechnology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

5 Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

6 Molecular Biology Research Center, System Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran


Objective(s): The present in vitro study aimed to evaluate whether Lactobacillus delbrueckii and Lactobacillus rhamnosus treatments can induce regulatory phenotype, together with modulating the expression of chemokine receptors (CRs) in dendritic cells (DCs). The CRs of DCs have been found to be involved in the pathogenesis of Systemic lupus erythematosus (SLE) through directing recruitment and migration of immune cells.
Materials and Methods: In brief, monocytes of patients with SLE and healthy donors were isolated and differentiated to regulatory or inflammatory mature DCs through treatment with L. delbrueckii, L. rhamnosus, mixed probiotics, and LPS. 
Results: FACScan analysis showed that the expression of CRs including CXCR3, CCR5, CCR4, and CCR3, was significantly reduced in all probiotic-treated groups of SLE and healthy (control) donors when compared with the LPS treated group. 
Conclusion: The results demonstrated that tolerogenic probiotics could prevent or decrease the expression of inflammatory CRs on the surface of tolerogenic DCs during the maturation process.  


1. Weidenbusch M, Kulkarni OP, Anders H-J. The innate immune system in human systemic lupus erythematosus. Clin Sc 2017; 131:625-634.
2. Pan L, Lu M-P, Wang J-H, Xu M, Yang S-R. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr 2019:1-12.
3. Atabati H, Esmaeili SA, Saburi E, Akhlaghi M, Raoofi A, Rezaei N, et al. Probiotics with ameliorating effects on the severity of skin inflammation in psoriasis: Evidence from experimental and clinical studies. J Cell Physiol 2020; 235:8925-8937.
4. Audiger C, Rahman MJ, Yun TJ, Tarbell KV, Lesage S. The importance of dendritic cells in maintaining immune tolerance.     J Immunol 2017; 198:2223-2231.
5. Radmanesh F, Mahmoudi M, Yazdanpanah E, Keyvani V, Kia N, Nikpoor AR, et al. The immunomodulatory effects of mesenchymal stromal cell‐based therapy in human and animal models of systemic lupus erythematosus. IUBMB life 2020; 72:2366-2381.
6. Esmaeili SA, Mahmoudi M, Rezaieyazdi Z, Sahebari M, Tabasi N, Sahebkar A, et al. Generation of tolerogenic dendritic cells using Lactobacillus rhamnosus and Lactobacillus delbrueckii as tolerogenic probiotics. J Cell Biochem 2018; 119:7865-7872.
7. Domogalla MP, Rostan PV, Raker VK, Steinbrink K. Tolerance through education: how tolerogenic dendritic cells shape immunity. Front Immunol 2017; 8:1764.
8. Kim CH. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:343-361.
9. Liao X, Pirapakaran T, Luo XM. Chemokines and chemokine receptors in the development of lupus nephritis. Mediators Inflamm 2016; 2016.
10. Seitz HM, Matsushima GK. Dendritic cells in systemic lupus erythematosus. Int Rev Immunol 2010; 29:184-209.
11. Turner J-E, Paust H-J, Bennstein SB, Bramke P, Krebs C, Steinmetz OM, et al. Protective role for CCR5 in murine lupus nephritis.     Am J Physiol Renal Physiol 2012; 302:F1503-F1515.
12. Bignon A, Gaudin F, Hémon P, Tharinger H, Mayol K, Walzer T, et al. CCR1 inhibition ameliorates the progression of lupus nephritis in NZB/W mice. J Immunol 2014; 192:886-896.
13. Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 2008; 19:1177-1189.
14. Yamada M, Yagita H, Inoue H, Takanashi T, Matsuda H, Munechika E, et al. Selective accumulation of CCR4+ T lymphocytes into renal tissue of patients with lupus nephritis.     Arthritis Rheum 2002; 46:735-740.
15. Eriksson C, Eneslätt K, Ivanoff J, Rantapää-Dahlqvist S, Sundqvist K-G. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003; 12:766-774.
16. Oppenheim JJ, Yang D, Biragyn A, Howard OZ, Plotz P. Chemokine receptors on dendritic cells promote autoimmune reactions. Arthritis Res Ther 2002; 4:S183.
17. Liu Y, Shi G. Role of G protein-coupled receptors in control of dendritic cell migration. Biomed Res Int 2014; 2014.
18. Wigren M, Nilsson J, Kaplan MJ. Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med 2015; 278:494-506.
19. Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: a cellular perspective. Trends Mol Med 2017; 23:615-635.
20. Esmaeili SA, Mahmoudi M, Momtazi AA, Sahebkar A, Doulabi H, Rastin M. Tolerogenic probiotics: potential immunoregulators in Systemic Lupus Erythematosus. J Cell Physiol 2017; 232:1994-2007.
21. Atabati H, Yazdanpanah E, Mortazavi H, Raoofi A, Esmaeili S-A, Khaledi A, et al. Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis. Adv Exp Med Biol 2021; 1286:87-105.
22. Ritprajak P, Kaewraemruaen C, Hirankarn N. Current paradigms of tolerogenic dendritic cells and clinical implications for systemic lupus erythematosus. Cells 2019; 8:1291.
23. Khorasani S, Mahmoudi M, Kalantari MR, Lavi Arab F, Esmaeili SA, Mardani F, et al. Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane‐induced lupus mice model. J Cell Physiol 2019; 234:9778-9786.
24. Mardani F, Mahmoudi M, Esmaeili SA, Khorasani S, Tabasi N, Rastin M. In vivo study: Th1–Th17 reduction in pristane‐induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. J Cell Physiol 2019; 234:642-649.
25. Evrard B, Coudeyras S, Dosgilbert A, Charbonnel N, Alamé J, Tridon A, et al. Dose-dependent immunomodulation of human dendritic cells by the probiotic Lactobacillus rhamnosus Lcr35. PLoS one 2011; 6:e18735.
26. De Laere M, Berneman ZN, Cools N. To the brain and back: migratory paths of dendritic cells in multiple sclerosis. J Neuropathol Exp Neurol 2018; 77:178-192.
27. García-López MÁ, Sánchez-Madrid F, Rodríguez-Frade JM, Mellado M, Acevedo A, García MI, et al. CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest 2001; 81:409-418.
28. Steinmetz OM, Turner J-E, Paust H-J, Lindner M, Peters A, Heiss K, et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis J Immunol 2009; 183:4693-4704.
29. Vahidi Z, Samadi M, Mahmoudi M, RezaieYazdi Z, Sahebari M, Tabasi N, et al. Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients. J Funct Foods 2018; 48:228-233.
30. Amoura Z, Combadiere C, Faure S, Parizot C, Miyara M, Raphaël D, et al. Roles of CCR2 and CXCR3 in the T cell–mediated response occurring during lupus flares. Arthritis Rheum 2003; 48:3487-3496.
31. Al-Saleh J, el-Eissawy S. The role of T helper cell subsets in pathogenesis of Systemic lupus erythematosus and their relation to disease activity. Egypt J Immuno 2006; 13:41-48.